Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.68 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23957346 | 0.91 | NLRP3 (0.55) | NLRP3LARS1GSTO1 | |
| SCHEMBL23957219 | 0.90 | NLRP3 (0.73) | NLRP3GSTO1 | |
| SCHEMBL23957234 | 0.89 | NLRP3 (0.53) | NLRP3LARS1GSTO1 | |
| SCHEMBL23957240 | 0.88 | NLRP3 (0.52) | NLRP3LARS1 | |
| SCHEMBL23957353 | 0.88 | NLRP3 (0.52) | NLRP3LARS1 | |
| SCHEMBL19519038 | 0.86 | NLRP3 (0.78) | NLRP3GSTO1 | |
| SCHEMBL29749496 | 0.85 | NLRP3 (0.49) | NLRP3LARS1GSTO1 | |
| SCHEMBL19518991 | 0.85 | NLRP3 (0.49) | NLRP3LARS1GSTO1 | |
| SCHEMBL19518818 | 0.82 | NLRP3 (0.72) | NLRP3GSTO1 | |
| SCHEMBL30406478 | 0.82 | NLRP3 (0.72) | NLRP3GSTO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332020-A1 | PHENYLSULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332020-A1 | PHENYLSULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | NLRP3 1/4885LARS1 986/4885CYP3A4 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.